Aarti Pharma
Drug Manufacturers - Specialty & Generic · AARTIPHARM
Mid CapHealthcareHigh Growth
Hetal Gogri Gala
Vice Chairperson & Managing Director · Pragmatic
Company DNA
Innovation-Led
About
Aarti Pharma is a Mid Cap company in the Healthcare sector, listed on NSE as AARTIPHARM. With a market cap of ₹6K Cr and revenue of ₹2K Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. High-growth pharma specialty business requiring R&D focus, scientific agility, and a culture centered on complex chemical product development. Its strategic mandate: To move up the value chain from basic APIs to complex, high-margin niche molecules, the firm needs a leader focused on R&D acceleration.
FAQ
What kind of company is Aarti Pharma?
Aarti Pharma is a Mid Cap Healthcare company (AARTIPHARM) in the High Growth phase with a market cap of ₹6K Cr. It is classified as Innovation-Led in culture.
What is Aarti Pharma's culture and work environment like?
Aarti Pharma has a Innovation-Led culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. High-growth pharma specialty business requiring R&D focus, scientific agility, and a culture centered on complex chemical product development.
Who leads Aarti Pharma?
Aarti Pharma is led by Hetal Gogri Gala (Vice Chairperson & Managing Director), a Pragmatic leader with 24 years of experience.
What are Aarti Pharma's financials?
Aarti Pharma reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of 20.5%. Operating margin: 18.1%. Market cap: ₹6K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
High-growth pharma specialty business requiring R&D focus, scientific agility, and a culture centered on complex chemical product development.
Mandate
To move up the value chain from basic APIs to complex, high-margin niche molecules, the firm needs a leader focused on R&D acceleration.
To move up the value chain from basic APIs to complex, high-margin niche molecules, the firm needs a leader focused on R&D acceleration.
Financials
Revenue FY25₹2K Cr
PAT FY25₹272 Cr
Rev CAGR 5Y20.5%
OPM18.1%
NPM13.1%
ROE13.7%
ROCE16.8%
P/E27.6
Fwd P/E—
P/B2.9
D/E33
Mkt Cap₹6K Cr
Promoter42.6%
Institutional12%
Similar Culture
Could You Lead Aarti Pharma?
Take the Genome Benchmark →